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Abstract
We have previously mapped the interval on Chromosome 4 for a major polycystic kidney
disease modifier (Mpkd) of the B6(Cg)-Cys1cpk/J mouse model of recessive polycystic kid-
ney disease (PKD). Informatic analyses predicted that this interval contains at least three
individual renal cystic disease severity-modulating loci (Mpkd1-3). In the current study, we
provide further validation of these predicted effects using a congenic mouse line carrying
the entire CAST/EiJ (CAST)-derivedMpkd1-3 interval on the C57BL/6J background. We
have also generated a derivative congenic line with a refined CAST-derivedMpkd1-2 inter-
val and demonstrated its dominantly-acting disease-modulating effects (e.g., 4.2-fold
increase in total cyst area; p<0.001). The relative strength of these effects allowed the use
of recombinants from these crosses to fine map theMpkd2 effects to a <14 Mbp interval
that contains 92 RefSeq sequences. One of them corresponds to the previously described
positionalMpkd2 candidate gene, Kif12. Among the positionalMpkd2 candidates, only
expression of Kif12 correlates strongly with the expression pattern of Cys1 across multiple
anatomical nephron structures and developmental time points. Also, we demonstrate that
Kif12 encodes a primary cilium-associated protein. Together, these data provide genetic
and informatic validation of the predicted renal cystic disease-modulating effects ofMpkd1-
3 loci and implicate Kif12 as the candidate locus forMpkd2.
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Introduction
The polycystic kidney diseases (PKD) are a major cause of end-stage renal disease [1]. Autoso-
mal dominant PKD (ADPKD; MIM 173900) is caused by mutations in the PKD1 or PKD2
genes [2–5] and autosomal recessive PKD (ARPKD; MIM 263200) results from mutations in
the PKHD1 gene [6, 7].
While ADPKD and ARPKD are considered to be classical Mendelian traits, the disease phe-
notypes in both forms of PKD are complex with respect to the severity of renal cystic disease
and extrarenal manifestations. Such phenotypic variability is typical even among family mem-
bers that share identical PKD mutations, suggesting modulating effects of other genetic (i.e.,
co-inherited modifier genes), epigenetic, or environmental factors (summarized by Mrug et al
[8]). Among these modulators of PKD progression, co-inherited modifier gene effects are the
most tractable for experimental investigation. Indeed, previous studies have identified several
quantitative trait locus (QTL) intervals that harbor genetic modifiers of PKD progression.
To date, the most significant QTL that modulates the severity of renal cystic and biliary phe-
notypes has been mapped to mouse Chromosome (Chr) 4 [9–12]. In previous studies, we have
performed intensive analyses of this interval and discriminated three individual QTL effects on
Chr 4 [8]. These effects were designated asMpkd1,Mpkd2 andMpkd3 (MGI:3603220–
3603222). Identification of specific candidate genes underlying the effects of theMpkd1-3 loci
has been complicated by the extensive span of the Chr 4 QTL complex (~50 cM corresponding
to over 100 Mbp of genomic sequence with ~1000 RefSeq genes). Therefore, we prioritized the
analyses of these positional candidates based on the reported expression in early postnatal kid-
neys and liver, differential renal expression in kidneys with slowly vs rapidly progressive cystic
kidney disease, and comparative analyses of genomic sequence in selected candidates. These
analyses implicated Kif12 as a strong positional candidate gene for theMpkd2 effects [8]. All of
these studies were performed in the well-characterized B6(Cg)-Cys1cpk/J (B6-Cys1cpk) mouse
model that phenotypically mimics ARPKD [8, 13–16]. The Cys1-encoded protein cystin is a
primary cilium-associated protein [13].
In the current study, we use congenic strain analyses to fine-map the predicted renal cystic
disease-modulating effects of theMpkd loci and provide further supportive evidence implicat-
ing Kif12 as the candidateMpkd2 locus based upon genetic, informatic, and immunolocaliza-
tion analyses.
Results
The congenic CAST/EiJ-derived interval containing theMpkd1-3 loci
modulates renal cystic disease severity
A congenic line homozygous for the CAST/EiJ (CAST)-derived proximal-medial segment of
Chr 4 on the C57BL/6J (B6) genetic background (B6.CAST.4PM) was developed previously by
mating (B6 × CAST)F1 females with B6 males; the male progeny with the desired microsatellite
marker profile were backcrossed to B6 females; mice at the N6 generation or later were inter-
crossed. Homozygous lines were selected for propagation [17].
We used a series of microsatellite markers to confirm the CAST origin of the Chr 4 interval
in the B6.CAST.4PM strain, to validate the B6 origin of the other Chromosomes, and to fine-
map the break point between the proximal CAST and distal B6 intervals on Chr 4, defined by
D4Mit11 and D4Mit204 (57.4–61.2 cM). We then interogressed the Cys1cpk mutation into this
mouse line using a (B6.CAST.4PM x B6-Cys1cpk/+) backcross and established a new line, B6.
CAST.4PM-Cys1cpk/+. We used the same backcross to generate a control Cys1cpk/+ line in
which the entire length of Chr 4 was derived from the B6 strain (B6.4PM-Cys1cpk/+). Since the
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CAST-derived Chr 4 interval in B6.CAST.4PM-Cys1cpk/+ line spans the threeMpkd1,Mpkd2
andMpkd3 loci (Fig 1a), this congenic line allowed us to more precisely evaluate the CAST-
derived effects that were identified in our previous studies.
In our initial studies, we characterized the renal cystic disease severity of 10-d old Cys1cpk/cpk
mice generated from the B6.CAST.4PM-Cys1cpk/+cross and compared it to the renal pheno-
types of Cys1cpk/cpk mice generated from the B6.4PM-Cys1cpk/+cross. These analyses revealed
strong disease-modulating effects of CAST-derivedMpkd1-3 loci, as evidenced by four indices
of cystic disease severity (Fig 1b). Specifically, kidney length (KL) increased 1.4-fold; total kid-
ney weight (KW), increased 3.3-fold (both p<0.001 by t-test; n = 12 for B6 and n = 7 for
CAST-derivedMpkd1-2 loci); KL adjusted for body length (crown to rump; BL), the KL/BL
ratio, increased 1.6-fold; and KW adjusted for body weight (BW), the KW/BW ratio, increased
by 4.2-fold (both p<0.001). These results are consistent with strong renal cystic disease-modu-
lating effects of the compositeMpkd1-3 locus. Since our experimental design compared the
impact of homozygosity for CAST-derived vs B6-derivedMpkd1-3 loci, the observed differ-
ences reflect the sum of various (e.g., dominant, recessive, and additive) disease phenotype-
modifyingMpkd1-3 effects.
The CAST-derivedMpkd1-2 locus has a dominantly-acting renal cystic
disease accelerating effect
Our previous studies suggested strong interactions among the individualMpkd1-3 loci [8]. As
the first step towards determining whether these loci may also act independently, we generated
a new Cys1cpk/+ congenic line, B6.CAST.4PM.P1, in which the CAST-derived Chr 4 interval
included only the proximal segment of Ch 4 that containsMpkd1 andMpkd2, but notMpkd3
(Fig 2a). The breakpoint between the proximal CAST and distal B6 intervals in this new line is
defined by D4Mit80 and D4Mit175 (37.7 cM and 45.7 cM).
To evaluate a subset of dominant renal cystic disease-promoting effects associated with
CAST-derivedMpkd1-2 loci, we generated Cys1cpk/cpk mice heterozygous for the CAST-derived
Mpkd1-2 loci and compared their renal cystic disease severity with Cys1cpk/cpk mice homozy-
gous for B6-derivedMpkd1-2 loci. These two groups were generated in the same B6.
CAST.4PM.P1 x B6-Cys1cpk/+ backcross. Phenotypic analysis at post-natal day 10 revealed
strong disease-accelerating effects of CAST-derivedMpkd1-2 loci, as evidenced by our indices
of cystic disease severity (Fig 2a). Specifically, KL increased by 1.3-fold; KW increased by
2.3-fold (both p<0.001 by t-test; n = 14 for B6- and n = 9- for CAST-derivedMpkd1-2 loci);
the KL/BL ratio increased by 1.2-fold; and the KW/BW ratio increased 1.9-fold (both
p<0.001). These results are consistent with a dominantly-acting, cystic disease-modulating
effect of the CAST-derivedMpkd1-2 loci.
Similar to the weight- and length-derived phenotypes (i.e., KW and KL), renal cystic indices
support the dominantly-acting cystic disease-modulating effects of the CAST-derivedMpkd1-2
locus. The total cyst area increased 4.2-fold, with the cyst area of the medulla increasing
3.9-fold and the cyst area of the cortex increasing 5.6-fold (all p<0.001). However, the CAST-
derivedMpkd1-2 locus had no effect on total cyst number or number of cysts in either the
medulla or the cortex (Table 1). These data suggest that theMpkd1-2 loci do not promote renal
cystogenesis per se, but rather modulate renal cystic disease severity.
Fine mapping of theMpkd2 effects
We adapted a deletion mapping approach [18, 19] to fine map the renal cystic disease-modu-
lating effects of theMpkd2 locus using 10-d old Cys1cpk/cpk Mpkd1-2 recombinants that were
generated from the B6.CAST.4PM.P1 x B6-Cys1cpk/+ backcross (Fig 3). Using this approach,
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we narrowed theMpkd2 interval to 14 Mbp defined by D4Mit288 and D4Mit83 (Chr 4 position
56,769,379 and 70.962.376). This interval contains 175 gene entries in the NCBI Map Viewer
(http://www.ncbi.nlm.nih.gov; NCBI Mus musculus Annotation Release 104), of which 116 are
RefSeq sequences and 59 sequences correspond to predicted, but as yet uncharacterized genes.
Among the RefSeq sequences, there are 92 protein-encoding genes, 3 microRNAs, and 21
pseudogenes.
We focused our subsequent evaluation of positionalMpkd2 candidates on the subset of the
RefSeq sequences that are expressed in the kidney and liver, the two organs that predomi-
nantly express the recessive PKD phenotypes [8]. Based on NCBI Unigene data (http://www.
ncbi.nlm.nih.gov), 33 of these RefSeq sequences are expressed in kidney and liver (Table 2),
and of these, 19 contain a single nucleotide polymorphism (SNP) variant based on compari-
son of B6 vs CAST genome sequence data (Wellcome Trust Sanger Institute, Mouse Genome
Project Data querying and visualization tool; http://www.sanger.ac.uk). Among these 19
sequences, 11 genes (Ikbkap, Svep1, AI314180, Fkbp15, Hdhd3, Kif12, Col27a1, Akna,Whrn,
Tlr4 and Cdk5rap2) contain at least one amino acid change that in the context of disease
would be predicted to be deleterious using software-based algorithms [20, 21]. In addition,
among the 33 kidney and liver expressed RefSeq sequences mapped to theMpkd2 interval, 6
genes (Ikbkap, Svep1, Fkbp15, Kif12, Col27a1 and Tlr4) contain an in frame insertion or dele-
tion variant.
Fig 1. Congenic CAST-derived interval containing theMpkd1-3 loci and its effects on renal cystic
disease progression. a) The CAST-derived segment of Chr 4 corresponding toMpkd1-3 interval is
delimited by the distal marker, D4Mit11 (shaded area); the breakpoint between proximal CAST-derived and
distal B6-derived segment of Chr 4 occurred between the markers, D4Mit11 (57.4 cM) and D4Mit204 (61.2
cM). b) The predicted cystic disease-modulating effects of the CAST-derivedMpkd1-3 loci were tested by
comparing surrogates of renal cystic phenotypes (kidney length and weight) inCys1cpk/cpkmutants
homozygous for the CAST-derived (CAST/Ei; n = 7) vs the B6-derived (B6; n = 12) segment of Chr 4. The
genetic background for both groups was B6. Diamonds represent values for individual animals. The line
indicates the mean value for each group.
doi:10.1371/journal.pone.0135678.g001
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Among theMpkd2-associated genes, Kif12 expression most closely
correlates with the structural and developmental expression pattern of
Cys1
To evaluate the relationships between the renal expression patterns of Cys1 and the genes that
map to theMpkd2 interval, we compared the transcriptional profiles across 18 different neph-
ron-derived anatomical structures and several development time points using the Genitouri-
nary Molecular Anatomy Project (GUDMAP) Database [http://www.gudmap.org; [22]].
Fig 2. Congenic CAST-derived interval containing theMpkd1-2 loci and its effects on renal cystic
disease progression. a) The CAST-derived segment of Chr 4 corresponding toMpkd1-2 interval is
delimited by the marker, D4Mit80 (shaded area). The breakpoint between the proximal CAST/E-derived and
distal B6-derived segment of Chr 4 occurred between markers D4Mit80 (37.7 cM) and D4Mit175 (45.7 cM).
b) The predicted cystic disease-modulating effects of the CAST-derivedMpkd1-2 loci was tested by
comparing the renal cystic phenotypes inCys1cpk/cpkmutants that were heterozygotes for the CAST-derived
(CAST/Ei; n = 9)Mpkd1-2 interval toCys1cpk/cpkmutants from the same cross that were homozygous B6 for
theMpkd1-2 interval (n = 14). The genetic background of both groups was B6. Diamonds represent values
for individual animals. The line indicates the mean value for each group.
doi:10.1371/journal.pone.0135678.g002









































B6.B6 average 554 13.4 1.9 14.2 371 6.9 1.6 23.6 184 6.6 0.3 4.3
SEM 14 0.2 0.0 0.2 9 0.1 0.0 0.3 6 0.1 0.0 0.1
CAST/
Ei.B6
average 532 19.7 7.9 37.1 335 11.8 6.4 50.2 197 7.8 1.6 17.9
SEM 11 0.7 0.5 1.4 8 0.5 0.4 1.5 6 0.2 0.1 1.2
p-value 0.750 0.002 <0.001 <0.001 0.424 0.001 <0.001 <0.001 0.659 0.057 <0.001 <0.001
all reported areas are in mm2; SEM = standard error of the mean; p-value = significance of differences between the B6.B6 and CAST/Ei.B6 averages
doi:10.1371/journal.pone.0135678.t001
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Among the top 100 of the ~40,000 GUDMAP transcript entries that most closely correlate
with the Cys1 expression pattern (S1 Fig), Kif12 ranked fourth in rank correlation (r = 0.819)
and was the only gene that mapped to theMpkd2 interval. Based on a comparison that used
Cys1 as the query to which all other transcripts in the GUDMAP Database were compared, the
Cys1 expression pattern was also highly correlated with the expression of several key cystogenic
genes (Fig 4), including Pkhd1 (correlation rank 69), the orthologue of principal human
ARPKD gene, andHnf1b (correlation rank 75), which encodes the transcription factor, hepato-
cyte nuclear factor-1beta (HNF1B) that directly regulates the expression of several cystogenic
Fig 3. Fine-mapping of renal cystic disease progression-modulatingMpkd2 effects.We adapted a
deletion mapping approach to fine map the dominant cystic disease-modulating effects of the CAST-derived
Mpkd2 locus using genetic recombinants for theMpkd1-2 interval that were generated from the B6.
CAST.4PM.P1-Cys1cpk/+ x B6-Cys1cpk/+ cross. Specifically, we refined the boundaries of theMpkd2 interval
with CAST-containingMpkd1-2 recombinants whose phenotypes (i.e., kidney length) were less than ~2 SD
of the phenotype distribution in the CASTMpkd1-2 interval homozygotes (black-filled diamonds). The
Mpkd1-2 interval is designated by light shading on upper panel). The refinedMpkd2 interval (dark shaded
area) is delimited by D4Mit288 (28.6 cM, 56.8 Mbp) and D4Mit83 (35.6 cM, 71.0 Mbp). It contains 92 RefSeq
sequences and Kif12maps to the center of this interval (dashed line). Consistent with the predicted cystic
disease-modulating effects of theMpkd2 locus, recombinants carrying the refinedMpkd2 interval of CAST
origin had more severe phenotypes (e.g., increased kidney length by 20%; p = 0.004) when compared to
recombinants that did not carry the CAST-derivedMpkd2 interval.
doi:10.1371/journal.pone.0135678.g003
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genes including Pkhd1 [summarized by Igarashi et al. [23]], Cys1 [24] and Kif12 [25]. Recipro-
cal analyses using Kif12 as the query revealed that Kif12 expression is correlated most strongly
with that of the Cys1 gene. Kif12 expression was also highly correlated with the expression of
Pkhd1 (correlation rank 26), and Hnf1b (correlation rank 15).
TheMpkd2 locus-associated gene Kif12 encodes a primary cilium-
associated protein
We have also demonstrated that the Kif12-encoded protein, member 12 (kinesin 12), co-local-
izes with the primary cilia markers somatostatin receptor 3 [26] and α-tubulin in a principal
Table 2. Positional candidates forMpkd2 effects: a subset expressed in kidney and liver.









of the AA change
Inframe insertion or
deletion variant in CAST
(vs B6)
Ikbkap 56763646 56815131 24 9 46 8 + single AA del
Ctnnal1 56823807 56878060 56 9 65 1 - -
Epb4.1l4b 53941976 54093158 8 62 14 3 - -
Txn1 57956245 57969283 96 45 84 - - -
Svep1 58055668 58219468 16 9 74 15 + single AA ins
AI314180 58812902 58925597 120 45 112 3 + -
Gng10 59048028 59054771 24 18 65 - - -
Ugcg 59189203 59222833 32 8 166 - - -
Hsdl2 59594463 59631566 282 36 46 - - -
E130308A19Rik 59639199 59767175 8 9 46 - - -
Inip 59769642 59783855 48 17 55 - - -
Mup4 59969678 59973537 8 7133 - 1 - -
Mup9 60418046 60421958 24 1849 - - - -
Mup1 60510886 60514832 32 4625 - - - -
Slc31a2 61947479 61959445 32 9 28 1 - -
Fkbp15 62300342 62360591 48 71 9 3 + single AA del x1, ins x2
Slc31a1 62021783 62052796 120 162 84 1 - -
Cdc26 62055623 62069657 32 63 56 - - -
Prpf4 62069817 62088024 32 9 28 - - -
Hdhd3 62160088 62163234 16 126 9 2 + -
Alad 62170204 62181097 137 298 93 - - -
Pole3 62184832 62186048 24 27 18 - - -
Rgs3 62220881 62363369 24 36 121 4 - -
Ambp 62804313 62815176 8 2018 - 2 - -
Kif12 62826671 62833165 282 9 280 3 + five-AA ins
Col27a1 62876446 62996025 16 27 56 13 + six-AA del
Akna 63028159 63064388 48 9 46 11 + -
Whrn 63075944 63156985 8 8 27 2 + -
Atp6v1g1 63205871 63211735 80 63 18 - - -
6330416G13Rik 63221390 63247389 32 9 9 - - -
Tlr4 66488845 66503831 16 18 74 9 + single-AA del
Cdk5rap2 69884058 70071401 40 9 28 12 + -
Megf9 70092961 70195962 8 36 224 3 - -
"TPM"—transcripts per million reported at UniGene; "AA"—amino acid
doi:10.1371/journal.pone.0135678.t002
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cell line derived from the mouse internal medullary collecting duct (mIMCD; Fig 5). This
observation provides the first evidence that anMpkd2 locus-associated gene encodes a primary
cilium-associated protein. Since the protein product of Cys1 localizes to primary cilium
together with most genes involved in renal cystic disease, localization of the Kif12 protein prod-
uct to primary cilia provides further support for this gene as anMpkd2 locus candidate.
Discussion
The strong renal cystic disease-modulating effects observed in Cys1cpk/cpk mice carrying the
CAST-derivedMpkd1-3 interval or itsMpkd1-2 derivative, provide further validation of our
initial QTL mapping studies that identified a major effect QTL on Chr 4 [8]. Importantly, the
current study demonstrates that theMpkd1-3 complex exerts its effects in a fashion that is
independent of previously identified non-Chr 4 QTL [8]. In addition, while our previous stud-
ies predicted interactions among genes in the Chr 4 QTL complex [8], the current study shows
that an isolatedMpkd1-2 interval, without theMpkd3 locus, is sufficient to exert a strong,
Fig 4. Kif12 expression patternmimics expression ofCys1. Among ~40,000 transcripts profiled in 18 different renal anatomical structures at different
developmental time-points that were deposited into the GUDMAPDatabase, Kif12was the only gene from theMpkd2 interval whose expression was highly
correlated with that ofCys1. Other non-Chr 4 genes with highly correlated expression patterns included Pkhd1, the mouse orthologue of the gene mutated in
virtually all cases of human ARPKD, andHnf1b, that encodes a direct transcriptional regulator of Pkhd1, Cys1 and Kif12. In addition,Hnf1bmutations result
in a renal cystic phenotype (MODY5 syndrome; MIM 137920). The heatmap depicts a subset of structures and developmental stages highly relevant to renal
cystic disease. Red shading corresponds to higher expression values; darker shading to lower values.
doi:10.1371/journal.pone.0135678.g004
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dominantly-acting effect on renal cystic disease severity. ThisMpkd1-2 QTL complex also
modulated the cystic area in the renal cortex and medulla, but did not influence cyst number.
Therefore, we propose that theMpkd1-2 locus most likely modulates progression of existing
renal cystic disease, rather than initiating new cyst formation, which may be regulated by other
factors known to impact cyst number, such as the renoprotective enzyme, heme oxygenase-1
[16].
We then went on to determine whether theMpkd2 interval alone contains a gene (or multi-
ple genes) with strong cystic disease-modulating effects. We developed a complementary set of
strategies to assess whether theMpkd2 effect could result from a coding sequence variant
within a subset of positional gene candidates that are expressed in kidney and liver, the two
organs that predominantly express the recessive PKD phenotypes. This approach identified 11
promising positionalMpkd2 candidates.
While multiple coding variant changes are present within the 11 genes that map to the this
interval (Table 2), only the expression of the previously described candidate, Kif12 [8], is
strongly correlated with the expression of Cys1 across the multiple anatomical nephron
Fig 5. Kinesin 12 localizes to primary apical cilium. Upper panel shows representative immunofluorescent micrographs of kinesin 12 (Kif12; red) co-
localized with a GFP-tagged primary cilia marker, somatostatin receptor 3 (Sstr3-GFP; green) in a mIMCD cell line expressing Sstr3-GFP. Lower panel
demonstrates co-localization of kinesin 12 with α-tubulin, another commonly used primary cilia marker. The right upper corner insert represents magnification
of the left uppermost primary apical cilium (highlighted in the lower left panel). Together, these data implicate kinesin 12 as a primary cilia-associated protein.
doi:10.1371/journal.pone.0135678.g005
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structures and developmental time points catalogued in the GUDMAP Database. While a com-
plete systematic evaluation of eachMpkd2 positional candidate on protein level is confounded
by limited immunoreagents, we have demonstrated that kinesin 12, the protein encoded by
Kif12, is a primary cilia-associated protein. Together, these data implicate Kif12 as a candidate
genetic modifier within theMpkd2 interval.
Our interpretation is further supported by the recently described localization of kinesin 12
to polycystin 1 (PC1) positive urinary exosome like vesicles [ELVs; [27]] together with Cys1,
Pkhd1 and Pkd2 encoded proteins. In addition, the expression of Kif12, Pkhd1 and Cys1, are
directly regulated byHNF1β [25]. Since Kif12 expression also strongly correlates with the
expression of HNF1 β, as well as Pkhd1 and Cys1 in the GUDMAP datasets, we propose that
these four genes may define a functional complex that together with Pkd1 [28, 29] modulates
the progression of recessive PKD (Fig 6).
Additional supporting evidence implicating Kif12 as theMpkd2modifier gene candidate is
provided by recent studies that demonstrate renal cystic disease-attenuating effects of Kif3a
deletion in Pkd1 and Pkd2mouse models [30]. Similarities between the N-terminal kinesin
motor domain and the C-terminal cargo-binding domain between kinesin 12 and kinesin 3a
[31] as well as kinesin 17 [32] suggest that kinesin 12 may complement the function of these
motor ciliary proteins. We speculate that the C57BL/6J-associated five amino acid deletion
within the kinesin 12 motor domain may impair function of this protein and have cystic dis-
ease-inhibiting effects similar to the Kif3a deletion. Kinesin 12 may also complement the func-
tion of other kinesins that direct biogenesis and function of primary cilia, e.g. through
regulation of microtubular dynamics [kinesin 7 [33]] or nucleation of cilia at centrioles [kine-
sin 24 [34]]. In addition, we note that kinesin 12 is expressed by macrophages [http://www.
ncbi.nlm.nih.gov/geo; e.g., GDS3554 and GDS3555 [35], and GDS2430 [36]] and the C57BL/
6J-associated deletion may alter their function. Macrophages induce proliferation of cystic epi-
thelial cells in the Cys1cpk and Pkd1models [37, 38] and their markers are abundantly
expressed in kidneys from ARPKD patients [15, 39, 40] as well as Cys1cpk/cpk mice carrying the
CAST-derived Kif12 allele [8, 15, 39].
However, it must be noted that unlike the well-studied anterograde IFT kinesins (e.g., kine-
sin 3a) that are conserved in most eukaryotic cells, kinesin 12 likely emerged later in evolution
[41], its orthologues appear only in mammals and birds together with orthologues of Pkhd1.
Cys1 so far has only been detected in mammals (based on NCBI Homologene; http://www.
ncbi.nlm.nih.gov). Therefore, while the data presented in this report and supporting evidence
from other recent studies are intriguing, they provide only circumstantial evidence for Kif12 as
theMpkd2 candidate gene. Further rigorous analyses, such targeted gene conversion experi-
ments, are required to validate Kif12 as theMpkd2 gene.
While the impact of modifier genes in modulating the ARPKD phenotype is suggested by
intrafamilial variability in disease expression [42–44], this proposition also has yet to be system-
atically evaluated. Such studies are complicated by compound heterozygosity for the majority of
low frequency PKHD1mutations. However, a recent study in South African Afrikaners demon-
strated a founder effect in which most ARPKD patients are homozygous for a single PKHD1
mutation and yet the clinical phenotypes in this cohort are variable [45]. Such populations pro-
vide powerful experimental resources for future studies to test the impact of KIF12 and other
specific candidate modifier genes on disease progression in human ARPKD. In addition, KIF12
variants may modulate the severity of a broader spectrum of hepato-renal fibrocystic disorders
or even trigger a ciliopathy such as KIF7mutation-induced Joubert syndrome [33].
In summary, we have performed functional validation of the renal cystic disease-modulating
effects associated with theMpkd1-3 interval. We have demonstrated that the CAST-derived
Mpkd1-2 interval promotes cystic disease progression independently of other loci and in a
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dominantly-acting fashion. We have usedMpkd1-2 recombinants to fine-map theMpkd2
locus to a 14 Mbp interval with 92 RefSeq sequences and developed convergent lines of experi-
mental evidence that implicate Kif12 as the principal candidate for theMpkd2 effects. This
work sets the stage for direct hypothesis testing of Kif12 as a genetic modifier using targeted
gene conversion experiments in cpkmice, as well as for initial directed studies of KIF12 as a
genetic modifier in specific human ARPKD populations, such as the Afrikaner cohort.
Materials and Methods
Mice
The C57BL/6J-Cys1cpk/+ mice were obtained from the Jackson Laboratory (Bar Harbor, ME).
The Cys1mutation arose spontaneously on the B6 background. The congenic line carrying the
CAST-derived proximal to medial segment of chromosome 4 (B6.CAST.4PM) on a B6 back-
ground [17]. This CAST fragment corresponds to theMpkd1-3 interval identified by our previ-
ous QTL mapping [8]. We have used non-recombinant F2 mice generated from a (B6.
CAST.4PM x B6-Cys1cpk/+)F1 intercross to establish homozygous B6.CAST.4PM-Cys1cpk/+ and
B6.4PM-Cys1cpk/+ mouse lines. Cystic disease severity in 10-d old Cys1cpk/cpk mice from the B6.
CAST.4PM-Cys1cpk/+ cross was compared to those generated in the B6.4PM-Cys1cpk/+ cross.
Scoring of phenotypes and genotyping with Cys1cpk allele-specific assay has been previously
described [8, 13].
Additional crosses were established to generate the congenic line B6.CAST.4PM.P1, with
the proximal Chr 4 QTL interval that contained theMpkd1-2 loci. To evaluate the cystic dis-
ease-modulating effects of the CAST-derivedMpkd1-2 interval, we backcrossed Cys1cpk/+ F1
mice from the B6.CAST.4PM x B6-Cys1cpk/+ cross to B6-Cys1cpk/+ mice. The resulting Cys1cpk/
cpk mice were screened for recombinants containing CAST-derived segments spanning the
proximal or distal portion of theMpkd1-2 interval.
Fig 6. Proposed integration of Kif12 into recessive PKD genetic pathway.Hnf1 β regulates the
transcription of several cystogenic genes including Pkhd1, the mouse orthologue of the principal ARPKD
gene;Cys1, the gene mutated in the cpkmodel of ARPKD, and Kif12, a candidate modifier of theCys1cpk/cpk
phenotype. Therefore, we propose that the four proteins encoded by Hnf1b, Cys1, Kif12, and Pkhd1may
define a functional complex that modulates the progression of recessive PKD (black font). This hypothesis is
supported by the very high correlations among structural and developmental expression patterns of these
four genes (Fig 4). In addition, components of the recessive PKD-associated pathway may interact at
different levels with functional components of ADPKD-associated pathways (white font). For example,
HNF1β also regulates the expression of Pkd2, an ADPKD gene. Furthermore, genetic interaction studies
suggest that abnormal Pkd1 expression sensitizes renal tubular cells to Pkhd1 defects [28, 29]. The latter
interaction may physically occur within the primary apical cilium (shaded oval), where these proteins all co-
localize. The proposed Kif12modulating effect on Cys1 function is designated by dashed line, solid lines
correspond to previously described relationships.
doi:10.1371/journal.pone.0135678.g006
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The integrity of CAST-derived Chr 4 intervals and the remaining B6 genome in these
mouse lines was confirmed using a microsatellite marker-based genome scan [8]. Microsatellite
makers were also used to fine-map the boundaries of CAST-B6 breakpoints on Chr 4.
All protocols were approved by the University of Alabama at Birmingham Institutional Ani-
mal Care and Use Committee. The University of Alabama at Birmingham is fully accredited by
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
International.
Histomorphometry
Paraffin-embedded kidneys were sectioned through the long axis and the hilus and stained
with hematoxylin and eosin. The histomorphometry was performed without knowledge of
experimental classifications using Bioquant Osteo 2013 Version 13.2.60 image analysis soft-
ware. The data was collected by examining: (i) Total tissue area; (ii) Total cyst area (the area
and number of cysts in the entire kidney was measured using void and outline filters in the
software, the cystic space criteria were set to>4X diameters of the normal proximal tubule
spaces; (iii) Medullary area (we estimated the boundary by using the glomeruli as cortical con-
trols), (iv) Medullary cyst area (by selecting the pixels in the cystic area within the medulla
boundary, we defined the medullary cysts using the same void and outline criteria as above;
these analyses also provided the medulla cyst count); (v) Boundary cysts: to optimize the accu-
racy of cyst counting, we created an array that allowed us to subtract the cysts from the medulla
if over 50% of the area was within the cortex. All other reported data were calculated as deriva-
tives of the above data. All data were independently validated by an additional reader using a
different microscope and image analysis software according to a previously described protocol
[16].
Cell culture and Immunostaining
The IMCD-K2 cell line derived from SV40 transformed internal medullary collecting duct cells
(mIMCD-K2; [46]) is a well-established renal principal cell line [39]. Cells were plated at con-
fluence and grown in DMEM/F12 medium containing Earle balanced salt solution supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin
(Thermo Fisher Scientific Inc; Waltham, MA), in 5% CO2/95% air at 37°C. Immunostaining
was performed after 3–4 d in culture.
The mIMCD-K2 cell line was stained using standard laboratory protocols. Briefly, the cells
were quickly fixed in -20°C methanol and rehydrated in PBS. We used polyclonal anti-mouse
α-tubulin antibody (Invitrogen Corporation, Carlsbad CA) and polyclonal anti-human kinesin
12 (N-18) antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibodies were
obtained from Invitrogen. Immunostaining was performed after blocking tissue sections for 30
min with PBS containing 1% bovine serum albumin (Sigma). Primary antibody diluted in
blocking buffer was incubated with the tissues for 12-hours at 4°C, followed by four rinses with
PBS. Nuclei were stained with Hoechst No. 33528 (Sigma) diluted 1:1,000 in PBS, rinsed 3
times in PBS, then mounted in Prolong Gold antifade mounting media (Molecular Probes). A
similar approach was applied to immunostaining of a mIMCD cell line stably expressing a
GFP-tagged somatostatin receptor 3; Sstr3-GFP [26]. Stained samples were analyzed using a
fluorescent Leica HC microscope (Leica, Allendale, NJ) and MetaMorph software (Molecular
Devices, Sunnyvale, CA).
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GUDMAP analyses
This study utilized data and analytical tools available from the NIDDK GUDMAP developing
kidney gene expression atlas database (http://www.gudmap.org; April 2011) including the
genome wide gene-expression datasets for developing kidney [22].
Statistical analyses
Statistical evaluations were performed with SPSS 11.5 statistical software package (SPSS Inc.).
Renal cystic phenotypes for both kidneys were combined to give an average phenotypic score
for each mouse. Significance of the differences between the two groups was determined by an
unpaired, two-tailed t-test.
Supporting Information
S1 Fig. Global genome-wide correlation of gene expression patterns to the one of Cys1.
Among ~40,000 transcripts profiled in 18 different renal anatomical structures at different
developmental time-points that were deposited into the GUDMAP Database, the Cys1 expres-
sion was highly correlated with theMpkd2 gene candidate, Kif12.
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